Device Trial Radar · NCT06297291
Global Paradise System US Post Approval Study
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Dec 2028
Study completion Jul 2031
Sponsor
- Lead sponsor
- ReCor Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.
Conditions
- Hypertension
- Cardiovascular Diseases
- Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation TreatmentDevice
The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure. Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary Endpoint #1: Group Mean BP reductionTime frame: Baseline to 3-months post-procedure
- Co-Primary Endpoint #2: Subject ResponderTime frame: Baseline to 3-months post-procedure
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
Tibor Rubin VA Medical Center
Long Beach, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Sutter Institute for Medical Research
Sacramento, California · Recruiting
43 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.